跳至主要内容
临床试验/NCT02968966
NCT02968966撤回2 期

Pathophysiologie Basierte Therapie Von früh Beginnenden Epileptischen Enzephalopathien

University Hospital Tuebingen2 个研究点 分布在 1 个国家开始时间: 2018年12月1日最近更新:
适应症

试验速览

阶段
2 期
状态
撤回
试验地点
2
主要终点
Reduction of seizures

研究概览

简要总结

Genetic epileptic encephalopathies (EEs) are a group of very rare and severe, pharmaco-resistant epilepsy forms characterized by an early onset, e.g. first years of life, and an often severe developmental delay. Genetic defects were found in different ion channels such as potassium or sodium channels explaining well the pathological neuronal hyperexcitability leading to seizures. Further mutations were also found in proteins relevant for cell structure, DNA/RNA processing or the synaptic vesicular metabolism. Specific and individualized therapies have not been established neither in the clinical routine nor in controlled studies. The goal of this monocentric non-blinded non-placebo controlled phase IIb study is the evaluation of the effectivity of anticonvulsive drugs specifically working on the ion channels defective in some subtypes of EEs in order to establish a standard and individualized therapy for these rare diseases based on the specific genetic defect.

详细描述

During the study, the sodium channel blockers phenytoin and lacosamide and the potassium channel blocker kinidinsulfate will be given under standardized conditions to patients with an early onset and pharmaco-resistant genetic epilepsy with and without mutations in the potassium channels KCNT1 and KCNQ2 and the sodium channel gene SCN2A. The primary endpoint will be a significant seizure reduction under trial medication compared to baseline. Secondary endpoints will be the improvement of electroencephalographic characteristics of the respective EEs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 12 Months(Child)
性别
All
接受健康志愿者

入选标准

  • highly active epilepsy (≥ 1 seizure per day)
  • epilepsy with onset 0-3 months of age
  • pharmaco-resistant epilepsy (2 or more standard anticonvulsive medications tried before)
  • recently max. two stable anticonvulsive drugs for minimum 4 days before study start
  • patients under continuous monitoring control
  • patients younger than 1 year of age

排除标准

  • high grade cardial rhythm disorders
  • severe liver, renal and electrolyte blood parameter changes
  • metabolic or lesional origin of epilepsy (metabolic screening results and cranial MRI available)
  • parallel participation in other studies (must be finished two month before study start)
  • missing informed consent

结局指标

主要结局

Reduction of seizures

时间窗: one week

Reduction of epileptic seizures within one treatment phase to 50% compared to baseline

次要结局

  • Reduction of seizures stratified for genetic background(one week)
  • Reduction of epileptic activities or suppression phases(one week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验